According to The British Society for Rheumatology guidelines, 5.6% of outpatients with rheumatoid arthritis (RA) in the West Midlands, UK, are eligible for anti-tumour necrosis factor (TNF) monoclonal antibody therapy

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.422, 2003-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Guidelines on the use of anti-tumour necrosis factor (TNF) therapies in patients with rheumatoid arthritis (RA) have been updated

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 475, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis

By Camussi G.   Lupia E.  

Drugs, Vol. 55, Iss. 5, 1998-05 ,pp. : 613-620

Adis International

Access to resources Recommend Favorite

Regional survey of tuberculosis risk assessment in rheumatology outpatients commencing anti-TNF-α treatment in relation to British Thoracic Society guidelines

By John H   Buckley C   Koh L   Obrenovic K   Erb N   Rowe IF  

Clinical Medicine, Vol. 9, Iss. 3, 2009-06 ,pp. : 225-230

Royal College Of Physicians

Access to resources Recommend Favorite

Anti-tumour necrosis factor therapy in seronegative spondyloarthritis

By Swales Catherine   Bowness Paul  

Clinical Medicine, Vol. 5, Iss. 3, 2005-05 ,pp. : 219-222

Royal College Of Physicians

Access to resources Recommend Favorite

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies: Update on Safety in Older Patients

By Ornetti Paul   Chevillotte Hélène   Zerrak Amal   Jean Francis Maillefert  

Drugs & Aging, Vol. 23, Iss. 11, 2006-01 ,pp. : 855-860

Adis International

Access to resources Recommend Favorite